Axsome Therapeutics (AXSM) saw a significant stock surge of 22.9% last month, driven by robust sales of its Auvelity antidepressant and a new FDA approval for treating agitation associated with Alzheimer’s disease. Launched in late 2022, Auvelity has rapidly become a key revenue driver, accounting for nearly 80% of the company’s sales, which grew by 66% last year. The FDA’s recent endorsement positions Auvelity as a non-antipsychotic alternative for a condition affecting over 5 million Americans, expanding its market potential significantly.
Analysts are optimistic about Axsome’s prospects, with Needham & Company and TD Cowen raising their price targets to $255 per share, reflecting a potential 23.5% upside from recent trading levels. The approval of Auvelity for Alzheimer’s agitation is particularly noteworthy, as it fills a critical gap in treatment options without the stigma associated with antipsychotic medications.
Investors should closely monitor Axsome’s upcoming first-quarter earnings report on May 4, as it may provide further insights into sales momentum and market strategy following this pivotal approval.
Source: fool.com